aTyr Pharma (NASDAQ:ATYR) Downgraded by HC Wainwright to Neutral

Key Points

• aTyr Pharma has been downgraded from a "buy" rating to a "neutral" rating by HC Wainwright, and other analysts have also issued negative ratings recently.
• The company's stock has plummeted 81.7% and is currently trading at $1.11, compared to a one-year high of $7.29.
• aTyr Pharma's quarterly earnings revealed a loss of ($0.22) earnings per share, missing analysts' estimates, and they are projected to have a EPS of -0.91 for the current year.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) was downgraded by research analysts at HC Wainwright from a "buy" rating to a "neutral" rating in a research report issued on Monday, MarketBeat.com reports.

Several other brokerages have also recently weighed in on ATYR. Jefferies Financial Group increased their price objective on shares of aTyr Pharma from $9.00 to $17.00 and gave the stock a "buy" rating in a research note on Friday, August 22nd. Leerink Partners reiterated a "market perform" rating on shares of aTyr Pharma in a research note on Monday. Cantor Fitzgerald cut shares of aTyr Pharma from an "overweight" rating to a "neutral" rating in a research note on Monday. Wall Street Zen cut shares of aTyr Pharma from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Finally, Wells Fargo & Company raised their target price on shares of aTyr Pharma from $17.00 to $25.00 and gave the stock an "overweight" rating in a research note on Friday, June 20th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, aTyr Pharma currently has an average rating of "Moderate Buy" and an average target price of $23.25.

aTyr Pharma Stock Down 83.2%

ATYR stock traded down $5.02 during trading on Monday, hitting $1.02. 145,316,777 shares of the stock traded hands, compared to its average volume of 3,514,365. aTyr Pharma has a 1 year low of $1.00 and a 1 year high of $7.29. The firm's 50 day moving average is $5.36 and its two-hundred day moving average is $4.39. The stock has a market cap of $99.46 million, a price-to-earnings ratio of -1.27 and a beta of 1.01. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.63 and a quick ratio of 5.63.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.04). On average, sell-side analysts anticipate that aTyr Pharma will post -0.91 EPS for the current year.

Institutional Trading of aTyr Pharma

Several institutional investors and hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System bought a new stake in shares of aTyr Pharma in the second quarter valued at about $28,000. Group One Trading LLC bought a new position in aTyr Pharma in the fourth quarter worth about $26,000. Ameritas Investment Partners Inc. purchased a new stake in aTyr Pharma during the 2nd quarter worth approximately $45,000. Legal & General Group Plc acquired a new position in shares of aTyr Pharma in the 2nd quarter valued at $49,000. Finally, Two Sigma Advisers LP acquired a new position in shares of aTyr Pharma in the fourth quarter valued at about $44,000. 61.72% of the stock is currently owned by institutional investors.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.